Shitanshu Uppal

Both treatment arms demonstrated clinically meaningful efficacy in patients with recurrent endometrial carcinoma. The combination of everolimus and letrozole showed a non-significant trend toward improved survival outcomes compared to standard hormonal therapy.

An intensive follow-up in patients treated for endometrial cancer does not improve overall survival or relapse detection significantly compared to a minimalist approach.

AP chemotherapy significantly improved both progression-free and overall survival compared to WAI in patients with advanced endometrial carcinoma, although it was associated with greater acute toxicity.

While postoperative radiotherapy reduces locoregional recurrence, it does not impact overall survival and increases treatment-related morbidity.